These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 32540876)

  • 1. Regulation of Glycemia in the Recovery Phase After Stroke Counteracts the Detrimental Effect of Obesity-Induced Type 2 Diabetes on Neurological Recovery.
    Augestad IL; Pintana H; Larsson M; Krizhanovskii C; Nyström T; Klein T; Darsalia V; Patrone C
    Diabetes; 2020 Sep; 69(9):1961-1973. PubMed ID: 32540876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity-induced type 2 diabetes impairs neurological recovery after stroke in correlation with decreased neurogenesis and persistent atrophy of parvalbumin-positive interneurons.
    Pintana H; Lietzau G; Augestad IL; Chiazza F; Nyström T; Patrone C; Darsalia V
    Clin Sci (Lond); 2019 Jul; 133(13):1367-1386. PubMed ID: 31235555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diet-induced weight loss in obese/diabetic mice normalizes glucose metabolism and promotes functional recovery after stroke.
    Karampatsi D; Zabala A; Wilhelmsson U; Dekens D; Vercalsteren E; Larsson M; Nyström T; Pekny M; Patrone C; Darsalia V
    Cardiovasc Diabetol; 2021 Dec; 20(1):240. PubMed ID: 34937562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalisation of glucose metabolism by exendin-4 in the chronic phase after stroke promotes functional recovery in male diabetic mice.
    Augestad IL; Dekens D; Karampatsi D; Elabi O; Zabala A; Pintana H; Larsson M; Nyström T; Paul G; Darsalia V; Patrone C
    Br J Pharmacol; 2022 Feb; 179(4):677-694. PubMed ID: 33973246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride.
    Darsalia V; Ortsäter H; Olverling A; Darlöf E; Wolbert P; Nyström T; Klein T; Sjöholm Å; Patrone C
    Diabetes; 2013 Apr; 62(4):1289-96. PubMed ID: 23209191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear magnetic resonance spectroscopy reveals biomarkers of stroke recovery in a mouse model of obesity-associated type 2 diabetes.
    Vieira JPP; Karampatsi D; Vercalsteren E; Darsalia V; Patrone C; Duarte JMN
    Biosci Rep; 2024 Jul; 44(7):. PubMed ID: 38864508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.
    Darsalia V; Olverling A; Larsson M; Mansouri S; Nathanson D; Nyström T; Klein T; Sjöholm Å; Patrone C
    Regul Pept; 2014 May; 190-191():25-31. PubMed ID: 24821550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging.
    Lietzau G; Magni G; Kehr J; Yoshitake T; Candeias E; Duarte AI; Pettersson H; Skogsberg J; Abbracchio MP; Klein T; Nyström T; Ceruti S; Darsalia V; Patrone C
    Neurobiol Aging; 2020 May; 89():12-23. PubMed ID: 32143981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Stroke-Induced Increase of Somatostatin-Expressing Neurons is Inhibited by Diabetes: A Potential Mechanism at the Basis of Impaired Stroke Recovery.
    Chiazza F; Pintana H; Lietzau G; Nyström T; Patrone C; Darsalia V
    Cell Mol Neurobiol; 2021 Apr; 41(3):591-603. PubMed ID: 32447613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway.
    Chiazza F; Tammen H; Pintana H; Lietzau G; Collino M; Nyström T; Klein T; Darsalia V; Patrone C
    Cardiovasc Diabetol; 2018 May; 17(1):60. PubMed ID: 29776406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.
    Biessels GJ; Janssen J; van den Berg E; Zinman B; Espeland MA; Mattheus M; Johansen OE;
    BMC Neurol; 2018 Jan; 18(1):7. PubMed ID: 29334906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A High-Fat Diet Increases Activation of the Glucagon-Like Peptide-1-Producing Neurons in the Nucleus Tractus Solitarii: an Effect that is Partially Reversed by Drugs Normalizing Glycemia.
    Lietzau G; Ntika S; Pintana H; Tracy L; Klein T; Nyström T; Darsalia V; Patrone C; Krizhanovskii C
    Cell Mol Neurobiol; 2022 Aug; 42(6):1995-2002. PubMed ID: 33811589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DPP-4 Inhibitor and Sulfonylurea Differentially Reverse Type 2 Diabetes-Induced Blood-Brain Barrier Leakage and Normalize Capillary Pericyte Coverage.
    Elabi OF; Karampatsi D; Vercalsteren E; Lietzau G; Nyström T; Klein T; Darsalia V; Patrone C; Paul G
    Diabetes; 2023 Mar; 72(3):405-414. PubMed ID: 36448982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin.
    Lietzau G; Davidsson W; Östenson CG; Chiazza F; Nathanson D; Pintana H; Skogsberg J; Klein T; Nyström T; Darsalia V; Patrone C
    Acta Neuropathol Commun; 2018 Feb; 6(1):14. PubMed ID: 29471869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity.
    Shao N; Yu XY; Yu YM; Li BW; Pan J; Wu WH; Zhang HJ; Ma XF; Hao M; Kuang HY
    Andrologia; 2018 Sep; 50(7):e13039. PubMed ID: 29740874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care.
    Patorno E; Gopalakrishnan C; Brodovicz KG; Meyers A; Bartels DB; Liu J; Kulldorff M; Schneeweiss S
    Diabetes Obes Metab; 2019 Aug; 21(8):1824-1836. PubMed ID: 30941884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of obesity-induced type 2 diabetes on long-term outcomes following stroke.
    Bhaskar S
    Clin Sci (Lond); 2019 Jul; 133(14):1603-1607. PubMed ID: 31331992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glimepiride and glibenclamide have comparable efficacy in treating acute ischemic stroke in mice.
    Wang X; Chang Y; He Y; Lyu C; Li H; Zhu J; Liu K; Hu Y; Huang K; Pan S
    Neuropharmacology; 2020 Jan; 162():107845. PubMed ID: 31704276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
    Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
    Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.